Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Erasca, Inc.

ERASNASDAQ
Healthcare
Biotechnology
$13.62
$-1.03(-7.03%)
U.S. Market opens in 14h 30m

Erasca, Inc. Fundamental Analysis

Erasca, Inc. (ERAS) shows weak financial fundamentals with a PE ratio of -31.68, profit margin of 0.00%, and ROE of -34.48%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

PEG Ratio-14.26
Current Ratio10.04

Areas of Concern

ROE-34.48%
Operating Margin0.00%
We analyze ERAS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -6.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-6.4/100

We analyze ERAS's fundamental strength across five key dimensions:

Efficiency Score

Weak

ERAS struggles to generate sufficient returns from assets.

ROA > 10%
-31.44%

Valuation Score

Excellent

ERAS trades at attractive valuation levels.

PE < 25
-31.68
PEG Ratio < 2
-14.26

Growth Score

Moderate

ERAS shows steady but slowing expansion.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
16.87%

Financial Health Score

Excellent

ERAS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.14
Current Ratio > 1
10.04

Profitability Score

Weak

ERAS struggles to sustain strong margins.

ROE > 15%
-3448.08%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is ERAS Expensive or Cheap?

P/E Ratio

ERAS trades at -31.68 times earnings. This suggests potential undervaluation.

-31.68

PEG Ratio

When adjusting for growth, ERAS's PEG of -14.26 indicates potential undervaluation.

-14.26

Price to Book

The market values Erasca, Inc. at 12.13 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

12.13

EV/EBITDA

Enterprise value stands at -30.76 times EBITDA. This is generally considered low.

-30.76

How Well Does ERAS Make Money?

Net Profit Margin

For every $100 in sales, Erasca, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-34.48 in profit for every $100 of shareholder equity.

-34.48%

ROA

Erasca, Inc. generates $-31.44 in profit for every $100 in assets, demonstrating efficient asset deployment.

-31.44%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.34 in free cash annually.

$-0.34

FCF Yield

ERAS converts -2.26% of its market value into free cash.

-2.26%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-31.68

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-14.26

vs 25 benchmark

P/B Ratio

Price to book value ratio

12.13

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.14

vs 25 benchmark

Current Ratio

Current assets to current liabilities

10.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.34

vs 25 benchmark

ROA

Return on assets percentage

-0.31

vs 25 benchmark

ROCE

Return on capital employed

-0.38

vs 25 benchmark

How ERAS Stacks Against Its Sector Peers

MetricERAS ValueSector AveragePerformance
P/E Ratio-31.6828.25 Better (Cheaper)
ROE-34.48%780.00% Weak
Net Margin0.00%-20122.00% (disorted) Weak
Debt/Equity0.140.30 Strong (Low Leverage)
Current Ratio10.044.66 Strong Liquidity
ROA-31.44%-14687.00% (disorted) Weak

ERAS outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Erasca, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-583.06%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-436.39%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ